Knight Therapeutics Inc.
KHTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $87 | $107 | $88 | $97 |
| % Growth | -18.7% | 21.9% | -9.1% | – |
| Cost of Goods Sold | $58 | $63 | $53 | $57 |
| Gross Profit | $29 | $45 | $35 | $40 |
| % Margin | 33.2% | 41.8% | 39.6% | 41.7% |
| R&D Expenses | $6 | $6 | $5 | $7 |
| G&A Expenses | $0 | $16 | $12 | $11 |
| SG&A Expenses | $22 | $31 | $26 | $25 |
| Sales & Mktg Exp. | $0 | $16 | $14 | $15 |
| Other Operating Expenses | $0 | $11 | $9 | $11 |
| Operating Expenses | $29 | $49 | $40 | $43 |
| Operating Income | $0 | -$4 | -$6 | -$3 |
| % Margin | 0.5% | -3.4% | -6.3% | -3.1% |
| Other Income/Exp. Net | -$2 | -$12 | $5 | $11 |
| Pre-Tax Income | -$1 | -$16 | -$0 | $8 |
| Tax Expense | $1 | -$3 | -$3 | -$3 |
| Net Income | -$3 | -$13 | $2 | $11 |
| % Margin | -3.1% | -11.8% | 2.5% | 11.1% |
| EPS | -0.027 | -0.13 | 0.022 | 0.11 |
| % Growth | 79% | -693.6% | -80.1% | – |
| EPS Diluted | -0.027 | -0.13 | 0.02 | 0.11 |
| Weighted Avg Shares Out | 100 | 100 | 100 | 97 |
| Weighted Avg Shares Out Dil | 100 | 100 | 100 | 101 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $2 | $3 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $13 | $12 | $12 | $14 |
| EBITDA | $13 | -$1 | $13 | $24 |
| % Margin | 15% | -1% | 14.7% | 25.1% |